Bernstein SocGen reiterates Outperform on Affirm stock at $110
Bernstein SocGen reiterated an Outperform rating on Affirm (AFRM) with a $110 price target, citing strong Q1 fiscal 2027 results. Revenue grew 33% YoY to $4.59B, but guidance raises were modest. Analysts noted mixed outlooks, with some raising targets (BofA to $109) and others lowering them (RBC to $83) due to delinquency concerns. AFRM stock is down 20% in 3 months, trading near fair value.
How this was made
The 30-second read
Why it matters
Analyst upgrades and target hikes indicate short‑term upside potential, but credit risk concerns remain.
Market read
AFRM's earnings beat and guidance raise provide a fresh catalyst that could move the stock in the near term.
What to watch
Potential impact of higher interest rates on consumer borrowing and AFRM's beta of 3.71.
Background
The article summarizes analyst reactions to AFRM's Q1 FY2027 earnings, including price target adjustments from several firms.
Ticker impact
Bernstein SocGen reiterated an Outperform rating on AFRM with a $110 price target after the company posted Q1 FY2027 earnings beat and raised guidance.
likely upward pressure as the market prices in the upgraded target and guidance raise.
The earnings beat and guidance raise are fresh primary disclosures, and multiple analysts moved targets higher, indicating a near‑term upside.
Market effects
Positive earnings may lift other BNPL and fintech peers.
U.S. consumer finance sector could see modest gains.
Limited to U.S. markets; no broader macro effect.
Counterpoint
Rising delinquencies and higher funding costs could weigh on margins, suggesting caution.
Key entities
- analystBernstein SocGen
Reiterated Outperform rating with $110 target.
- analystBofA Securities
Raised price target to $109.
- analystRBC Capital
Lowered target to $83 due to credit concerns.
